NASDAQ:AKTX - Akari Therapeutics Stock Price, Price Target & More

$1.96 +0.01 (+0.51 %)
(As of 04/23/2018 04:00 PM ET)
Previous Close$1.96
Today's Range$1.85 - $2.02
52-Week Range$1.70 - $20.00
Volume27,347 shs
Average Volume151,427 shs
Market Capitalization$22.97 million
P/E Ratio-7.00
Dividend YieldN/A
Beta-7.65

About Akari Therapeutics (NASDAQ:AKTX)

Akari Therapeutics logoAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. The company is based in New York, New York. Akari Therapeutics, Plc is a subsidiary of RPC Pharma Limited.

Receive AKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKTX
CUSIPN/A
Phone44-20-8004-0270

Debt

Debt-to-Equity RatioN/A
Current Ratio3.19%
Quick Ratio2.38%

Price-To-Earnings

Trailing P/E Ratio-7.00
Forward P/E Ratio-1.05
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.70 per share
Price / Book1.15

Profitability

EPS (Most Recent Fiscal Year)($0.28)
Net Income$-32,570,000.00
Net MarginsN/A
Return on Equity-187.46%
Return on Assets-122.21%

Miscellaneous

Employees15
Outstanding Shares11,780,000

How to Become a New Pot Stock Millionaire

Akari Therapeutics (NASDAQ:AKTX) Frequently Asked Questions

What is Akari Therapeutics' stock symbol?

Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics (NASDAQ:AKTX) released its earnings results on Wednesday, March, 21st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.66) by $0.59. View Akari Therapeutics' Earnings History.

When is Akari Therapeutics' next earnings date?

Akari Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May, 21st 2018. View Earnings Estimates for Akari Therapeutics.

What price target have analysts set for AKTX?

4 Wall Street analysts have issued 12-month price objectives for Akari Therapeutics' stock. Their predictions range from $2.50 to $8.00. On average, they expect Akari Therapeutics' stock price to reach $4.50 in the next twelve months. View Analyst Ratings for Akari Therapeutics.

What are Wall Street analysts saying about Akari Therapeutics stock?

Here are some recent quotes from research analysts about Akari Therapeutics stock:
  • 1. According to Zacks Investment Research, "Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5, preventing release of C5a and formation of C5b-9. Akari Therapeutics PLC, formerly known as Celsus Therapeutics Plc, is based in London, United Kingdom. " (1/16/2018)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: September 21, 2017, 23:12 ET Date and time of production: September 21, 2017, 20:41 ET Target Price / Valuation Methodology: Impax Laboratories – IPXL Our $19 price target is derived from a blend of DCF (7.7% WACC, +1% terminal growth) and a 9.2x forward EV/EBITDA on our 2018 estimates. IPXL shares currently trade around 8x our 2018 EV/EBITDA compared to a group average of around 9.2x. We think a group average EV/EBITDA valuation is warranted because of potential P&L leverage growing profitability faster than revenue which warrants a premium, a premium warranted for the company’s well-respected leadership offset by a discount to the group for relatively low expected top-line growth and a low-duration FTF/FTM based generics pipeline." (9/22/2017)

Who are some of Akari Therapeutics' key competitors?

Who are Akari Therapeutics' key executives?

Akari Therapeutics' management team includes the folowing people:
  • Dr. Ray Prudo M.D., Exec. Chairman (Age 73)
  • Mr. Dov Elefant, Chief Financial Officer (Age 51)
  • Mr. Clive Richardson, COO & Director (Age 53)
  • Dr. David Horn Solomon M.D., CEO & Director (Age 58)
  • Dr. Miles Nunn, Chief Scientific Officer

Has Akari Therapeutics been receiving favorable news coverage?

Media coverage about AKTX stock has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Akari Therapeutics earned a news sentiment score of 0.12 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.99 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Akari Therapeutics?

Shares of AKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Akari Therapeutics' stock price today?

One share of AKTX stock can currently be purchased for approximately $1.96.

How big of a company is Akari Therapeutics?

Akari Therapeutics has a market capitalization of $22.97 million. The biopharmaceutical company earns $-32,570,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis. Akari Therapeutics employs 15 workers across the globe.

How can I contact Akari Therapeutics?

Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The biopharmaceutical company can be reached via phone at 44-20-8004-0270 or via email at [email protected]


MarketBeat Community Rating for Akari Therapeutics (AKTX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  105 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  196
MarketBeat's community ratings are surveys of what our community members think about Akari Therapeutics and other stocks. Vote "Outperform" if you believe AKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Akari Therapeutics (NASDAQ:AKTX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Akari Therapeutics in the last 12 months. Their average twelve-month price target is $4.50, suggesting that the stock has a possible upside of 129.59%. The high price target for AKTX is $8.00 and the low price target for AKTX is $2.50. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.672.67
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.50$6.8333$8.75$8.75
Price Target Upside: 129.59% upside212.02% upside6.97% upside6.97% upside

Akari Therapeutics (NASDAQ:AKTX) Consensus Price Target History

Price Target History for Akari Therapeutics (NASDAQ:AKTX)

Akari Therapeutics (NASDAQ:AKTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2018Canaccord GenuityLower Price TargetBuy -> Buy$15.00 -> $8.00LowView Rating Details
2/8/2018B. RileyInitiated CoverageNeutral -> Neutral$3.00HighView Rating Details
9/22/2017William BlairUpgradeMarket Perform -> OutperformHighView Rating Details
9/17/2017Chardan CapitalReiterated RatingNeutralLowView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Akari Therapeutics (NASDAQ:AKTX) Earnings History and Estimates Chart

Earnings by Quarter for Akari Therapeutics (NASDAQ:AKTX)

Akari Therapeutics (NASDAQ:AKTX) Earnings Estimates

2018 EPS Consensus Estimate: ($2.70)
2019 EPS Consensus Estimate: ($0.04)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.66)($0.66)($0.66)
Q2 20181($0.53)($0.53)($0.53)
Q3 20181($0.68)($0.68)($0.68)
Q4 20181($0.83)($0.83)($0.83)
Q1 20191($0.01)($0.01)($0.01)
Q2 20191($0.01)($0.01)($0.01)
Q3 20191($0.01)($0.01)($0.01)
Q4 20191($0.01)($0.01)($0.01)

Akari Therapeutics (NASDAQ AKTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/21/2018        
3/21/2018Not Specified($0.66)($0.07)ViewListenView Earnings Details
11/13/2017Q3 2017($1.00)($0.09)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.70)($0.06)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.54)($0.09)ViewN/AView Earnings Details
3/31/2017Q4 2016($0.08)ViewN/AView Earnings Details
11/10/2016Q3 2016$0.03ViewN/AView Earnings Details
8/11/2016Q2 2016($0.45)ViewN/AView Earnings Details
11/23/2015Q3 2015($0.03)ViewN/AView Earnings Details
1/7/2014Q4 2012($1.90)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Akari Therapeutics (NASDAQ:AKTX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Akari Therapeutics (NASDAQ AKTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 61.80%
Institutional Ownership Percentage: 32.94%
Insider Trading History for Akari Therapeutics (NASDAQ:AKTX)
Institutional Ownership by Quarter for Akari Therapeutics (NASDAQ:AKTX)

Akari Therapeutics (NASDAQ AKTX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/18/2015Mark S CohenDirectorBuy1,055,600$0.19$200,564.001,055,600View SEC Filing  
4/15/2014Sabby Management, LlcMajor ShareholderBuy20,100$5.03$101,103.00View SEC Filing  
4/11/2014Sabby Management, LlcMajor ShareholderBuy2,575$5.35$13,776.25View SEC Filing  
4/8/2014Sabby Management, LlcMajor ShareholderBuy68,404$5.59$382,378.36View SEC Filing  
4/2/2014Sabby Management, LlcMajor ShareholderBuy28,207$6.22$175,447.54View SEC Filing  
3/27/2014Sabby Management, LlcMajor ShareholderBuy16,203$6.66$107,911.98View SEC Filing  
3/24/2014Sabby Management, LlcMajor ShareholderBuy11,100$6.83$75,813.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Akari Therapeutics (NASDAQ AKTX) News Headlines

Source:
DateHeadline
Zacks: Analysts Anticipate Akari Therapeutics (AKTX) Will Announce Earnings of -$0.66 Per ShareZacks: Analysts Anticipate Akari Therapeutics (AKTX) Will Announce Earnings of -$0.66 Per Share
www.americanbankingnews.com - April 23 at 11:10 PM
Akari Therapeutics (AKTX) Outperform Rating Reaffirmed at William BlairAkari Therapeutics' (AKTX) Outperform Rating Reaffirmed at William Blair
www.americanbankingnews.com - April 19 at 11:52 PM
Q1 2018 EPS Estimates for Akari Therapeutics (AKTX) Raised by AnalystQ1 2018 EPS Estimates for Akari Therapeutics (AKTX) Raised by Analyst
www.americanbankingnews.com - April 18 at 7:58 AM
Zacks: Brokerages Anticipate Akari Therapeutics (AKTX) to Post -$1.00 Earnings Per ShareZacks: Brokerages Anticipate Akari Therapeutics (AKTX) to Post -$1.00 Earnings Per Share
www.americanbankingnews.com - April 6 at 11:20 PM
Akari Therapeutics PLC (AKTX) Given Average Recommendation of "Hold" by BrokeragesAkari Therapeutics PLC (AKTX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 30 at 1:32 AM
Akari Therapeutics (AKTX) Given New $8.00 Price Target at Canaccord GenuityAkari Therapeutics (AKTX) Given New $8.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - March 29 at 2:29 PM
Akari Therapeutics PLC (AKTX) Forecasted to Earn Q1 2018 Earnings of ($1.00) Per ShareAkari Therapeutics PLC (AKTX) Forecasted to Earn Q1 2018 Earnings of ($1.00) Per Share
www.americanbankingnews.com - March 26 at 1:06 AM
William Blair Comments on Akari Therapeutics PLCs Q1 2019 Earnings (AKTX)William Blair Comments on Akari Therapeutics PLC's Q1 2019 Earnings (AKTX)
www.americanbankingnews.com - March 23 at 1:21 PM
Akari Therapeutics (AKTX) Posts  Earnings ResultsAkari Therapeutics (AKTX) Posts Earnings Results
www.americanbankingnews.com - March 22 at 10:22 AM
Edited Transcript of AKTX earnings conference call or presentation 21-Mar-18 12:30pm GMTEdited Transcript of AKTX earnings conference call or presentation 21-Mar-18 12:30pm GMT
finance.yahoo.com - March 22 at 9:44 AM
Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical ... - GlobeNewswire (press release)Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical ... - GlobeNewswire (press release)
globenewswire.com - March 21 at 4:25 PM
Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical ProgressAkari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical Progress
finance.yahoo.com - March 21 at 10:38 AM
Akari Therapeutics (AKTX) to Release Earnings on WednesdayAkari Therapeutics (AKTX) to Release Earnings on Wednesday
www.americanbankingnews.com - March 17 at 8:14 PM
Akari Therapeutics To Report Fourth Quarter and Full Year 2017 Financial and Operational Results and Host Conference Call on March 21, 2018Akari Therapeutics To Report Fourth Quarter and Full Year 2017 Financial and Operational Results and Host Conference Call on March 21, 2018
finance.yahoo.com - March 16 at 9:46 AM
Head-To-Head Contrast: Akari Therapeutics (AKTX) versus Clementia Pharmaceuticals (CMTA)Head-To-Head Contrast: Akari Therapeutics (AKTX) versus Clementia Pharmaceuticals (CMTA)
www.americanbankingnews.com - March 10 at 9:22 PM
684,000 Shares in Akari Therapeutics PLC (AKTX) Acquired by AWM Investment Company Inc.684,000 Shares in Akari Therapeutics PLC (AKTX) Acquired by AWM Investment Company Inc.
www.americanbankingnews.com - March 6 at 4:45 AM
Akari Therapeutics PLC (AKTX) Given Consensus Recommendation of "Hold" by BrokeragesAkari Therapeutics PLC (AKTX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 5 at 1:30 AM
Contrasting Flex Pharma (FLKS) & Akari Therapeutics (AKTX)Contrasting Flex Pharma (FLKS) & Akari Therapeutics (AKTX)
www.americanbankingnews.com - March 3 at 9:12 PM
Zacks: Analysts Expect Akari Therapeutics PLC (AKTX) to Post -$1.00 EPSZacks: Analysts Expect Akari Therapeutics PLC (AKTX) to Post -$1.00 EPS
www.americanbankingnews.com - March 3 at 7:20 PM
Zacks: Brokerages Anticipate Akari Therapeutics PLC (AKTX) Will Announce Earnings of -$1.00 Per ShareZacks: Brokerages Anticipate Akari Therapeutics PLC (AKTX) Will Announce Earnings of -$1.00 Per Share
www.americanbankingnews.com - February 15 at 3:16 AM
Akari Therapeutics PLC Forecasted to Earn FY2017 Earnings of ($3.00) Per Share (AKTX)Akari Therapeutics PLC Forecasted to Earn FY2017 Earnings of ($3.00) Per Share (AKTX)
www.americanbankingnews.com - February 12 at 1:08 AM
Akari Therapeutics (AKTX) Coverage Initiated at B. RileyAkari Therapeutics (AKTX) Coverage Initiated at B. Riley
www.americanbankingnews.com - February 11 at 3:24 PM
Akari Therapeutics to Present at the Leerink Partners Global Healthcare ConferenceAkari Therapeutics to Present at the Leerink Partners Global Healthcare Conference
finance.yahoo.com - February 8 at 8:55 AM
Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical TrialsAkari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials
finance.yahoo.com - February 6 at 9:07 AM
Head to Head Contrast: Kura Oncology (KURA) and Akari Therapeutics (AKTX)Head to Head Contrast: Kura Oncology (KURA) and Akari Therapeutics (AKTX)
www.americanbankingnews.com - February 1 at 9:12 PM
 Analysts Expect Akari Therapeutics PLC (AKTX) to Post -$1.00 Earnings Per Share Analysts Expect Akari Therapeutics PLC (AKTX) to Post -$1.00 Earnings Per Share
www.americanbankingnews.com - January 29 at 3:14 AM
Akari Therapeutics Strengthens Board with Two Senior Industry AppointmentsAkari Therapeutics Strengthens Board with Two Senior Industry Appointments
finance.yahoo.com - January 23 at 8:19 AM
 Brokerages Set $2.50 Target Price for Akari Therapeutics PLC (AKTX) Brokerages Set $2.50 Target Price for Akari Therapeutics PLC (AKTX)
www.americanbankingnews.com - January 22 at 3:36 PM
Akari Therapeutics (AKTX) Stock Rating Lowered by Zacks Investment ResearchAkari Therapeutics (AKTX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 16 at 4:36 PM
Zacks: Akari Therapeutics PLC (AKTX) Given Consensus Rating of "Buy" by AnalystsZacks: Akari Therapeutics PLC (AKTX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - January 13 at 5:34 PM
Akari Therapeutics PLC (AKTX) Expected to Post Earnings of -$1.00 Per ShareAkari Therapeutics PLC (AKTX) Expected to Post Earnings of -$1.00 Per Share
www.americanbankingnews.com - January 12 at 5:14 AM
Penumbra (PEN) Forms JV on Virtual Reality in Health Space ... - NasdaqPenumbra (PEN) Forms JV on Virtual Reality in Health Space ... - Nasdaq
www.nasdaq.com - January 6 at 5:43 AM
Anika Therapeutics Receives FDA Nod for Bone Repair Therapy - NasdaqAnika Therapeutics Receives FDA Nod for Bone Repair Therapy - Nasdaq
www.nasdaq.com - January 5 at 2:10 PM
Thermo Fisher Buys Phenom-World, Aids Analytical Instruments - NasdaqThermo Fisher Buys Phenom-World, Aids Analytical Instruments - Nasdaq
www.nasdaq.com - January 5 at 2:10 PM
Audentes Therapeutics (BOLD) Jumps: Stock Rises 14.9%Audentes Therapeutics (BOLD) Jumps: Stock Rises 14.9%
finance.yahoo.com - January 5 at 2:10 PM
New Products Aid Boston Scientific, LOTUS Relaunch Lag AilsNew Products Aid Boston Scientific, LOTUS Relaunch Lag Ails
www.zacks.com - January 3 at 3:51 PM
Zacks: Akari Therapeutics PLC (AKTX) Given $2.50 Consensus Price Target by AnalystsZacks: Akari Therapeutics PLC (AKTX) Given $2.50 Consensus Price Target by Analysts
www.americanbankingnews.com - December 29 at 5:52 AM
Array BioPharma (ARRY) Looks Good: Stock Adds 9.6% in SessionArray BioPharma (ARRY) Looks Good: Stock Adds 9.6% in Session
finance.yahoo.com - December 26 at 12:11 PM
Amarin Corporation (AMRN) in Focus: Stock Moves 8.9% HigherAmarin Corporation (AMRN) in Focus: Stock Moves 8.9% Higher
finance.yahoo.com - December 21 at 11:07 AM
Zacks: Akari Therapeutics PLC (AKTX) Receives Average Recommendation of "Buy" from BrokeragesZacks: Akari Therapeutics PLC (AKTX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 14 at 5:40 PM
Tenet Healthcare (THC) in Focus: Stock Moves 8.5% HigherTenet Healthcare (THC) in Focus: Stock Moves 8.5% Higher
finance.yahoo.com - December 13 at 11:31 AM
Alexion (ALXN) in Focus: Stock Moves 7.2% HigherAlexion (ALXN) in Focus: Stock Moves 7.2% Higher
finance.yahoo.com - December 11 at 11:50 AM
Akari Therapeutics (AKTX) and Sarepta Therapeutics (SRPT) Financial ComparisonAkari Therapeutics (AKTX) and Sarepta Therapeutics (SRPT) Financial Comparison
www.americanbankingnews.com - December 5 at 9:32 PM
Akari: December Coversin Update, Analysts Opinion and CatalystsAkari: December Coversin Update, Analysts Opinion and Catalysts
finance.yahoo.com - December 2 at 3:49 PM
Akari Therapeutics (AKTX) Upgraded by ValuEngine to SellAkari Therapeutics (AKTX) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - November 30 at 11:02 PM
Brokerages Anticipate Akari Therapeutics PLC (AKTX) to Announce ($1.00) Earnings Per ShareBrokerages Anticipate Akari Therapeutics PLC (AKTX) to Announce ($1.00) Earnings Per Share
www.americanbankingnews.com - November 28 at 8:02 AM
ANI Pharmaceuticals (ANIP) Catches Eye: Stock Jumps 17.7%ANI Pharmaceuticals (ANIP) Catches Eye: Stock Jumps 17.7%
finance.yahoo.com - November 27 at 10:18 AM
Zacks: Brokerages Expect Akari Therapeutics PLC (AKTX) to Announce -$1.00 EPSZacks: Brokerages Expect Akari Therapeutics PLC (AKTX) to Announce -$1.00 EPS
www.americanbankingnews.com - November 21 at 3:26 AM
European ADRs Inch Higher in Monday SessionEuropean ADRs Inch Higher in Monday Session
www.nasdaq.com - November 20 at 3:21 PM
FY2017 Earnings Estimate for Akari Therapeutics PLC Issued By William Blair (AKTX)FY2017 Earnings Estimate for Akari Therapeutics PLC Issued By William Blair (AKTX)
www.americanbankingnews.com - November 17 at 9:44 PM

SEC Filings

Akari Therapeutics (NASDAQ:AKTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Akari Therapeutics (NASDAQ:AKTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Akari Therapeutics (NASDAQ AKTX) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.